News
Background: Clinical trial designs have historically been biased towards the Caucasian population, with limited ...
In the annals of corporate fraud, few stories resonate as powerfully as that of Theranos, the Silicon Valley biotech startup ...
For the first time ever, three groups of students from grades six to nine were given the opportunity to wow a panel of judges ...
Everyone should become an eco-warrior, Minister for General Education V. Sivankutty has said. He was speaking after performing the State-level inauguration of ‘Kalpakam’ under the higher secondary ...
At the heart of Trade 350 App lies a proprietary AI engine that continuously learns and evolves. Rather than relying on ...
Q1 2025 Earnings Conference Call June 5, 2025 8:00 AM ETCompany ParticipantsJasmine Lee - Corporate ParticipantBoard Secretary ...
The president’s agenda has exposed how vulnerable the region’s economy is to punitive, ideologically driven federal policy.
Limited ("Meanwhile" or the "Company"), the world's first life insurance company fully denominated in Bitcoin ("BTC"), today announced the completion and public release of its 2024 audited financial ...
Sharjah’s innovation ecosystem collaborates with private sector to enable testing of advanced medical solutions ...
It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...
Optiscan CEO Dr. Camile Farah delves into the company’s technology and capabilities that have positioned it as a leader ...
StockStory.org on MSN1d
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services StocksLet’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results